Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost ...

The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, 2024, as the Federal Reserve announced its first interest-rate cut since ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

ResMed Inc. closed $4.30 below its 52-week high ($255.18), which the company reached on September 9th.

Major U.S. indexes were little changed at midday Wednesday, ahead of the Federal Reserve's decision on interest rates.

Wolfe Research downgraded shares of the maker of sleep-apnea airway machines to Underperform from Peer Perform.

ResMed achieved double-digit revenue growth through acquisitions and operating efficiencies, with improving capital ...

ResMed faces a 3% drop in share price after concerns over Eli Lilly’s Ozempic, which could impact the demand for CPAP ...

ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...

The ResMed Inc (ASX: RMD) is having a shocker today, down more than 3.5%. Why is this ASX 200 healthcare stock on the nose?

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to ...

Wolfe Research has recently reduced Resmed Inc (RMD) stock to Underperform rating, as announced on September 18, 2024, according to Finviz. Earlier, on September 4, 2024, Needham had reduced the stock ...